Imara, Inc.
(NASDAQ : IMRA)

( )
IMRA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.36%53.730.9%$2003.48m
JNJJohnson & Johnson -0.10%166.500.7%$976.03m
ABBVAbbVie, Inc. -0.13%134.991.9%$909.01m
MRKMerck & Co., Inc. -0.32%81.060.7%$859.37m
BMYBristol-Myers Squibb Co. -0.44%64.441.0%$686.20m
LLYEli Lilly & Co. 0.81%247.061.1%$628.58m
AZNAstraZeneca Plc 1.24%60.221.0%$242.02m
NVSNovartis AG -0.26%88.610.2%$195.20m
GSKGlaxoSmithKline Plc -0.64%45.400.2%$164.17m
NVONovo Nordisk A/S -0.97%96.340.1%$153.51m
VTRSViatris, Inc. 0.27%14.760.0%$141.42m
RGENRepligen Corp. 0.00%189.586.7%$99.89m
IMMXImmix Biopharma, Inc. 0.71%5.700.0%$89.42m
ALLKAllakos, Inc. 0.27%7.450.0%$87.86m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.04%115.080.0%$71.65m

Company Profile

Imara, Inc. is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Boston, MA.